T2 Biosystems Inc. (NASDAQ:TTOO) rose 2.6% on Wednesday . The company traded as high as $5.12 and last traded at $5.09, with a volume of 284,536 shares changing hands. The stock had previously closed at $4.96.

Several equities research analysts recently weighed in on the company. Canaccord Genuity cut their price objective on T2 Biosystems from $13.00 to $12.00 and set a “buy” rating on the stock in a report on Tuesday, April 12th. Janney Montgomery Scott downgraded T2 Biosystems from a “buy” rating to a “neutral” rating in a report on Tuesday, April 12th. Leerink Swann reissued an “outperform” rating and set a $11.00 price objective (down previously from $13.00) on shares of T2 Biosystems in a report on Tuesday, April 12th. Zacks Investment Research downgraded T2 Biosystems from a “hold” rating to a “sell” rating in a report on Tuesday, April 19th. Finally, Cantor Fitzgerald reissued a “buy” rating on shares of T2 Biosystems in a report on Tuesday, May 3rd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $10.90.

The stock has a 50-day moving average of $8.17 and a 200 day moving average of $8.85. The company’s market capitalization is $124.09 million.

T2 Biosystems (NASDAQ:TTOO) last issued its earnings results on Monday, May 2nd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by $0.01. During the same quarter in the previous year, the business posted ($0.53) EPS. The business had revenue of $1.10 million for the quarter. T2 Biosystems’s revenue was up 485.1% on a year-over-year basis. On average, equities research analysts anticipate that T2 Biosystems Inc. will post ($2.17) earnings per share for the current year.

In other news, SVP Rahul Dhanda sold 3,589 shares of the company’s stock in a transaction on Thursday, June 30th. The shares were sold at an average price of $8.16, for a total value of $29,286.24. Following the transaction, the senior vice president now owns 3,589 shares of the company’s stock, valued at $29,286.24. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

An institutional investor recently raised its position in T2 Biosystems stock. Aisling Capital LLC boosted its stake in T2 Biosystems Inc. (NASDAQ:TTOO) by 12.2% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 2,830,992 shares of the company’s stock after buying an additional 307,692 shares during the period. T2 Biosystems makes up about 5.3% of Aisling Capital LLC’s portfolio, making the stock its 6th largest position. Aisling Capital LLC owned 13.89% of T2 Biosystems worth $30,971,000 at the end of the most recent quarter.

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.